A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine–tipiracil with bevacizumab in patients with metastatic colorectal cancer☆
A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine–tipiracil with bevacizumab in patients with metastatic colorectal cancer☆. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426068870?dgcid=rss_sd_all
A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine–tipiracil with bevacizumab in patients with metastatic colorectal cancer☆. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426068870?dgcid=rss_sd_all
“A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine–tipiracil with bevacizumab in patients with metastatic colorectal cancer☆.” Annals of Oncology.
@article{article36249,
title = {A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine–tipiracil with bevacizumab in patients with metastatic colorectal cancer☆},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426068870?dgcid=rss_sd_all}
}